ReviewCurrent neuropharmacology2018
Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis.
Review in Current neuropharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Empathy and Theory of Mind in Multiple Sclerosis: A Meta-Analysis.Frontiers in psychiatry · 2021Pooled it
- The immediate effect of stroboscopic visual training on information-processing time in people with multiple sclerosis: an exploratory study.Journal of neural transmission (Vienna, Austria : 1996) · 2020Trial
- PET-MRI effects of N-acetylcysteine in patients with multiple sclerosis.IBRO neuroscience reports · 2026Article
- Exploring Social Cognition Sub-Domains and Predictors in Multiple Sclerosis: A Cross-Sectional Study.Brain and behavior · 2025Article
- Long-Term Management and Therapeutic Sequencing for Patients with Relapsing Multiple Sclerosis in France: A Vignette Study.Neurology and therapy · 2025Article
- Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- The effect of atomoxetine on cognitive function in patients with multiple sclerosis.Current journal of neurology · 2023Article
- Exploring the impact of exercise and essential amino acid plus cholecalciferol supplementation on physical fitness and body composition in multiple sclerosis: A case study.Clinical case reports · 2023Article
- Article
- Non-Pharmacological Treatments of Cognitive Impairment in Multiple Sclerosis: A Review.NeuroSci · 2022Review
- Increased Levels of Beta-Endorphin and Noradrenaline after a Brief High-Impact Multidimensional Rehabilitation Program in Multiple Sclerosis.Life (Basel, Switzerland) · 2022Article
- Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis.Caspian journal of internal medicine · 2022Article
- Managing Chronic Neuropathic Pain: Recent Advances and New Challenges.Neurology research international · 2022Review
- Cognitive impairment in multiple sclerosis: diagnosis and monitoring.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- The Role of Nutritional Lifestyle and Physical Activity in Multiple Sclerosis Pathogenesis and Management: A Narrative Review.Nutrients · 2021Review
- Article
- Empathy and theory of mind in multiple sclerosis: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Social cognition in multiple sclerosis and its subtypes: A protocol for systematic review and meta-analysis.Medicine · 2020Article
- Treatment and management of cognitive dysfunction in patients with multiple sclerosis.Nature reviews. Neurology · 2020Review
- Cognitive Dysfunction in the Early Stages of Multiple Sclerosis-How Much and How Important?Current neurology and neuroscience reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCognitive impairment is one of the most important clinical features of neurodegenerative disorders including multiple sclerosis (MS). Conducted research shows that up to 65 percent of MS patients have cognitive deficits such as episodic memory, sustained attention, reduced verbal fluency; however, the cognitive MS domain is information processing speed. It is the first syndrome of cognitive dysfunction and the most widely affected in MS. Occasionally these impairments occur even before the appearance of physical symptoms.
methodsTherefore, this review focused on the current status of our knowledge about possible methods of treatment cognitive impairment in MS patients including novel strategies. Research and online content was performed using Medline and EMBASE databases.
resultsThe most recent research suggests that cognitive impairment is correlated with brain lesion volume and brain atrophy. The examination of the cognitive impairment is usually based on particular neuropsychological batteries. However, it can be not enough to make a precise diagnosis. This creates a demand to find markers that might be useful for identifying patients with risk of cognitive impairment at an early stage of the disease. Currently the most promising methods consist of neuroimaging indicators, such as diffusion tensor imaging, the magnetization transfer ratio, and N-acetyl aspartate levels. Diagnosis problems are strictly connected with treatment procedures. There are two main cognitive therapies: pharmacological (disease modifying drugs (DMD), symptomatic treatments) and non-pharmacological interventions that are focused on psychological and physical rehabilitation. Some trials have shown a positive association between physical activity and the cognitive function.
conclusionThis article is an overview of the current state of knowledge related to cognition impairment treatment in MS. Additionally, novel strategies for cognitive impairments such as cryostimulation and other complementary methods are presented.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.